Aminopeptidase N‐Responsive Conjugates with Tunable Charge‐Reversal Properties for Highly Efficient Tumor Accumulation and Penetration
- 24 January 2023
- journal article
- research article
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 62 (9) , e202217408
Abstract
Tumor enzyme‐responsive charge‐reversal carriers can induce efficient transcytosis and lead to efficient tumor infiltration and potent anticancer efficacy. However, the correlations of molecular structure with charge‐reversal property, tumor penetration, and drug delivery efficiency are unknown. Herein, aminopeptidase N (APN)‐responsive conjugates were synthesized to investigate these correlations. We found that the monomeric unit structure and the polymer chain structure determined the enzymatic hydrolysis and charge‐reversal rates, and accordingly, the transcytosis and tumor accumulation and penetration of the APN‐responsive conjugates. The conjugate with moderate APN responsiveness balanced the in vitro transcytosis and in vivo overall drug delivery process and achieved the best tumor delivery efficiency, giving potent antitumor efficacy. This work provides new insight into the design of tumor enzyme‐responsive charge‐reversal nanomedicines for efficient cancer drug delivery.Keywords
Funding Information
- National Key Research and Development Program of China (2021YFA1201200)
- China Postdoctoral Science Foundation (2021M692762)
This publication has 46 references indexed in Scilit:
- Aminopeptidase N (CD13) as a target for cancer chemotherapyCancer Science, 2011
- Management of breast cancer with targeted agents: importance of heterogenicityNature Reviews Clinical Oncology, 2010
- Charge‐Reversal Drug Conjugate for Targeted Cancer Cell Nuclear Drug DeliveryAdvanced Functional Materials, 2009
- The moonlighting enzyme CD13: old and new functions to targetTrends in Molecular Medicine, 2008
- Canalicular immunostaining of aminopeptidase N (CD13) as a diagnostic marker for hepatocellular carcinomaJournal of Clinical Pathology, 2005
- Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: Chemistry, biological evaluations, and therapeutic prospectsMedicinal Research Reviews, 2005
- Aminopeptidase N in Sera of Healthy Subjects Is a Different N-Terminal Processed Derivative from the One Obtained from Maternal SerumMolecular Genetics and Metabolism, 1998
- Families of zinc metalloproteasesFEBS Letters, 1994
- Role of aminopeptidase N (CD13) in tumor‐cell invasion and extracellular matrix degradationInternational Journal of Cancer, 1993
- Potent and systemically active aminopeptidase N inhibitors designed from active-site investigationJournal of Medicinal Chemistry, 1992